103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024
HB3180

 

Introduced 2/17/2023, by Rep. Tom Weber

 

SYNOPSIS AS INTRODUCED:
 
720 ILCS 570/210  from Ch. 56 1/2, par. 1210

    Amends the Illinois Controlled Substances Act. Adds Clonazolam as a Schedule IV controlled substance.


LRB103 29935 RLC 56350 b

 

 

A BILL FOR

 

HB3180LRB103 29935 RLC 56350 b

1    AN ACT concerning criminal law.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4    Section 5. The Illinois Controlled Substances Act is
5amended by changing Section 210 as follows:
 
6    (720 ILCS 570/210)  (from Ch. 56 1/2, par. 1210)
7    Sec. 210. (a) The controlled substances listed in this
8Section are included in Schedule IV.
9    (b) Unless specifically excepted or unless listed in
10another schedule, any material, compound, mixture, or
11preparation containing limited quantities of any of the
12following narcotic drugs, or their salts calculated as the
13free anhydrous base or alkaloid, as set forth below:
14        (1) Not more than 1 milligram of difenoxin (DEA Drug
15    Code No. 9618) and not less than 25 micrograms of atropine
16    sulfate per dosage unit.
17        (2) Dextropropoxyphene (Alpha-(+)-4-dimethylamino-1,
18    2-diphenyl-3-methyl-2-propionoxybutane).
19    (c) Unless specifically excepted or unless listed in
20another schedule, any material, compound, mixture, or
21preparation which contains any quantity of the following
22substances having a potential for abuse associated with a
23depressant effect on the central nervous system:

 

 

HB3180- 2 -LRB103 29935 RLC 56350 b

1        (1) Alprazolam;
2        (2) Barbital;
3        (2.1) Bromazepam;
4        (2.2) Camazepam;
5        (2.3) Carisoprodol;
6        (3) Chloral Betaine;
7        (4) Chloral Hydrate;
8        (5) Chlordiazepoxide;
9        (5.1) Clobazam;
10        (6) Clonazepam;
11        (6.1) Clonazolam;
12        (7) Clorazepate;
13        (7.1) Clotiazepam;
14        (7.2) Cloxazolam;
15        (7.3) Delorazepam;
16        (8) Diazepam;
17        (8.05) Dichloralphenazone;
18        (8.1) Estazolam;
19        (9) Ethchlorvynol;
20        (10) Ethinamate;
21        (10.1) Ethyl loflazepate;
22        (10.2) Fludiazepam;
23        (10.3) Flunitrazepam;
24        (11) Flurazepam;
25        (11.1) Fospropofol;
26        (12) Halazepam;

 

 

HB3180- 3 -LRB103 29935 RLC 56350 b

1        (12.1) Haloxazolam;
2        (12.2) Ketazolam;
3        (12.3) Loprazolam;
4        (13) Lorazepam;
5        (13.1) Lormetazepam;
6        (14) Mebutamate;
7        (14.1) Medazepam;
8        (15) Meprobamate;
9        (16) Methohexital;
10        (17) Methylphenobarbital (Mephobarbital);
11        (17.1) Midazolam;
12        (17.2) Nimetazepam;
13        (17.3) Nitrazepam;
14        (17.4) Nordiazepam;
15        (18) Oxazepam;
16        (18.1) Oxazolam;
17        (19) Paraldehyde;
18        (20) Petrichloral;
19        (21) Phenobarbital;
20        (21.1) Pinazepam;
21        (22) Prazepam;
22        (22.1) Quazepam;
23        (23) Temazepam;
24        (23.1) Tetrazepam;
25        (23.2) Tramadol;
26        (24) Triazolam;

 

 

HB3180- 4 -LRB103 29935 RLC 56350 b

1        (24.5) Zaleplon;
2        (25) Zolpidem;
3        (26) Zopiclone.
4    (d) Any material, compound, mixture, or preparation which
5contains any quantity of the following substances, including
6its salts, isomers (whether optical, position, or geometric),
7and salts of such isomers, whenever the existence of such
8salts, isomers and salts of isomers is possible:
9        (1) Fenfluramine.
10    (e) Unless specifically excepted or unless listed in
11another schedule any material, compound, mixture, or
12preparation which contains any quantity of the following
13substances having a stimulant effect on the central nervous
14system, including its salts, isomers (whether optical,
15position or geometric), and salts of such isomers whenever the
16existence of such salts, isomers, and salts of isomers is
17possible within the specific chemical designation:
18        (1) Cathine ((+)-norpseudoephedrine);
19        (1.1)   Diethylpropion;
20        (1.2) Fencamfamin;
21        (1.3) Fenproporex;
22        (2) Mazindol;
23        (2.1) Mefenorex;
24        (3) Phentermine;
25        (4) Pemoline (including organometallic complexes and
26    chelates thereof);

 

 

HB3180- 5 -LRB103 29935 RLC 56350 b

1        (5) Pipradrol;
2        (6) SPA ((-)-1-dimethylamino-1, 2-diphenylethane);
3        (7) Modafinil;
4        (8) Sibutramine.
5    (f) Other Substances. Unless specifically excepted or
6unless listed in another schedule, any material, compound,
7mixture, or preparation that contains any quantity of the
8following substance, including its salts:
9        (1) Butorphanol (including its optical isomers).
10    (g) The Department may except by rule any compound,
11mixture, or preparation containing any depressant substance
12listed in subsection (b) from the application of all or any
13part of this Act if the compound, mixture, or preparation
14contains one or more active medicinal ingredients not having a
15depressant effect on the central nervous system, and if the
16admixtures are included therein in combinations, quantity,
17proportion, or concentration that vitiate the potential for
18abuse of the substances which have a depressant effect on the
19central nervous system.
20    (h) Except as otherwise provided in Section 216, any
21material, compound, mixture, or preparation that contains any
22quantity of the following substance having a stimulant effect
23on the central nervous system, including its salts,
24enantiomers (optical isomers) and salts of enantiomers
25(optical isomers):
26        (1) Ephedrine, its salts, optical isomers and salts of

 

 

HB3180- 6 -LRB103 29935 RLC 56350 b

1    optical isomers.
2(Source: P.A. 97-334, eff. 1-1-12.)